Table 3.
Subgroup analysis of the meta-analysis
| Outcomes | Subgroup | Number of trials | Effect (95% CI) | Estimate for overall effect | Heterogeneity |
|---|---|---|---|---|---|
| Pain | Total(1 day) | 4 | −0.38(−1.01,0.24) | P = 0.231 | I2 = 82.1%, P = 0.001 |
| VAS(1 day) | 3 | −0.59 (−1.45, 0.27) | P = 0.181 | I2 = 86.1%, P = 0.001 | |
| VAS and VRS(1 day) | 1 | 0.16 (− 0.35, 0.66) | P = 0.545 | ||
| Total(3 day) | 6 | −0.53(−1.02,0.05) | P = 0.032 | I2 = 75.7%, P = 0.001 | |
| VAS(3 day) | 5 | −0.67 (−1.26, − 0.08) | P = 0.026 | I2 = 78.6%, P = 0.001 | |
| VAS and VRS (3 day) | 1 | −0.01 (− 0.51, 0.50) | P = 0.975 | ||
| Total(7 day) | 4 | −1.05 (−2.14, 0.03) | P = 0.057 | I2 = 90.3%, P < 0.001 | |
| VAS(7 day) | 3 | − 1.62 (−3.63, 0.39) | P = 0.113 | I2 = 93.2%, P < 0.001 | |
| VAS and VRS (7 day) | 1 | 0.07 (− 0.44, 0.58) | P = 0.786 | ||
| Trismus | Total | 4 | −0.19 (− 0.88, 0.50) | P = 0.596 | I2 = 73.1%, P = 0.011 |
| Ustun method | 3 | −0.46 (− 0.99, 0.07) | P = 0.088 | I2 = 39.7%, P = 0.190 | |
| Other | 1 | 0.77 (0.04, 1.50) | P = 0.039 |
VAS visual analogue scale, VRS verbal scale